Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRKY
REST API REST API
Homo sapiens
PRKY is differentially expressed in 211 experiments: 83 organism parts: lung, ovary, ... (81 more);, 130 disease states: normal, acute lymphoblastic leukemia, ... (128 more);, 61 cell types 256 cell lines 15 compound treatments and 61 other conditions.
Synonyms PRKYP, PRKXP3
Search EB-eye ENSG00000099725
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-GEOD-6573, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, ... (33 experiments)

Factor Value U/D Experiments
HCC2157
2
 E-MTAB-37, E-MTAB-62
MOLT4
2
 E-MTAB-62, E-MTAB-37
U87
2
 E-GEOD-20089, E-MEXP-903
CROAP2
1
 E-MTAB-37
HT3
1
 E-MTAB-37
NA18498
1
 E-GEOD-19480
250 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (35 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
3
5
 E-GEOD-16190, E-AFMX-5, E-TABM-145, E-GEOD-6740
mononuclear
2
 E-GEOD-13987, E-GEOD-26672
endothelial cell
1
 E-GEOD-3920
leydig cell
1
 E-MTAB-25
CD4 positive T-cell
1
1
 E-GEOD-6338
effector memory T cell
1
 E-GEOD-3982
55 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-15960, E-GEOD-2466, ... (36 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
 E-MTAB-62, E-MEXP-2034, E-GEOD-96
lung adenocarcinoma
1
2
 E-MTAB-37, E-MTAB-62, E-MEXP-231
acute lymphoblastic leukemia
1
2
 E-MTAB-62, E-GEOD-96, E-MTAB-37
synovial sarcoma
1
 E-MTAB-37
colon adenocarcinoma, acterial infection
1
 E-MTAB-62
juvenile idiopathic arthritis subtype oligoarthritis
1
 E-GEOD-13501
124 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-3284, E-GEOD-412, E-TABM-782, E-TABM-127, ... (12 experiments)

Factor Value U/D Experiments
none
2
5
 E-MEXP-1958, E-GEOD-412, E-GEOD-7400, E-GEOD-5824, E-TABM-782, ... (7 experiments)
lipopolysaccharide
2
 E-MEXP-1958, E-TABM-868
bacterial endotoxin
1
1
 E-GEOD-3284
control
30
1
 E-GEOD-3284
filtered air
1
 E-TABM-127
cigarette smoke
2
1
 E-TABM-127
9 more value(s).


Biosource provider

studied in E-GEOD-20559

Factor Value U/D Experiments
Fox Chase Cancer Center Biorepository
1
1
 E-GEOD-20559


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-2034, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-3013

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-20847, E-GEOD-6431

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, E-GEOD-17347, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-GEOD-20504 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-GEOD-974, E-GEOD-1926, E-GEOD-3720, E-TABM-26, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-360

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-21750, E-GEOD-1460

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-5851, E-GEOD-19743, E-GEOD-20153, E-GEOD-1643, E-GEOD-19069, ... (23 experiments)

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-23984

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.443 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM